Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lymphoma, Gene Abnormality. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Detailed description
This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.
Primary outcome measures
- Incidence of driver gene abnormalities [Time frame: from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months]
Secondary outcome measures (3)
- objective response rate [Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months]
- 5-year overall survival [Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years]
- Clinicopathological Characteristics [Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months]
Eligibility criteria
Inclusion criteria
- Diagnosed as lymphoma (according to WHO 2017 classification criteria)
- Life expectancy no less than 3 months
- Agreeing to sign the written informed consents
Exclusion criteria
- Other malignant tumor history or active malignant tumor need be treated
- Researchers determine unsuited to participate in this trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university — Zhengzhou
Identifiers
NCT: NCT04263935 · HNCH2019341